New antibody aims to stop bleeding episodes in rare clotting disorder
NCT ID NCT06211634
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests an experimental antibody called HMB-001 in 57 adults with Glanzmann thrombasthenia, a rare bleeding disorder. The study aims to see if the drug is safe and can reduce the number and severity of bleeds when given regularly. Participants receive single or multiple doses over several months, with close monitoring for side effects and bleeding events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HMB-001 (a lab-made antibody given as a shot to help prevent bleeding)
What this could lead to
If it works, this could offer a way to prevent frequent, dangerous bleeds in people with Glanzmann thrombasthenia, reducing the need for emergency treatment.
What could go wrong
This is a very early first-in-human trial with only 57 people, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to reduce bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLANZMANN THROMBASTHENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM - Hopital de la Timone
Marseille, France
-
AP-HP Hopital Bicetre (Part B/C)
Le Kremlin-Bicêtre, France
-
AP-HP Hopital Necker-Enfants Malades (Part B/C)
Paris, France
-
Azienda Ospedaliero-Universitaria Careggi (Part B/C)
Florence, Italy
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano (Part B/C)
Milan, Italy
-
Hemophilia Center of Western Pennsylvania (HCWP) (Part B/C)
Pittsburgh, Pennsylvania, 15213, United States
-
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
-
Mayo Clinic - Rochester (Part B/C)
Rochester, Minnesota, 55905, United States
-
Queen Elizabeth Hospital Birmingham (Part B/C)
Birmingham, United Kingdom
-
Richmond Pharmacology Ltd (Part A/B/C)
London, United Kingdom
-
Royal Free London NHS Foundation Trust (Part B/C)
London, United Kingdom
-
The Royal London Hospital (Part B/C)
Whitechapel, United Kingdom
-
Tulane University Medical Center (Part B/C)
New Orleans, Louisiana, 70112, United States
-
Universitair Medisch Centrum Utrecht (Part B/C)
Utrecht, Netherlands
-
University Hospital Leuven - Campus Gasthuisberg (Part B/C)
Leuven, Belgium
-
University of California, San Diego (UCSD) (Part B/C)
La Jolla, California, 92093, United States
-
Washington Institute for Coagulation (Part B/C)
Seattle, Washington, 98101, United States